ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H & Thisted, R K 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet. Infectious diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Johansen, I S & Larsen, L 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet Infectious Diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 The Lancet. Infectious Diseases
Clinical Trials r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname medRxiv article-version (status) pre article-version (number) 2 Clin Trials Murray, D D, Babiker, A G, Baker, J V, Barkauskas, C E, Brown, S M, Chang, C C, Davey, V J, Gelijns, A C, Ginde, A A, Grund, B, Higgs, E, Hudson, F, Kan, V L, Lane, H C, Murray, T A, Paredes, R, Parmar, M K B, Pett, S, Phillips, A N, Polizzotto, M N, Reilly, C, Sandkovsky, U, Sharma, S, Teitelbaum, M, Thompson, B T, Young, B E, Neaton, J D & Lundgren, J D 2022, ' Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents : Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) ', Clinical Trials, vol. 19, no. 1, pp. 52-61 . https://doi.org/10.1177/17407745211049829
ACTIV-3/TICO LY-CoV555 Study Group 2021, ' A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 ', The New England Journal of Medicine, vol. 384, no. 10, pp. 905-914 . https://doi.org/10.1056/NEJMoa2033130 The New England Journal of Medicine ACTIV-3/TICO LY-CoV555 Study Group 2021, ' A neutralizing monoclonal antibody for hospitalized patients with Covid-19 ', New England Journal of Medicine, vol. 384, no. 10, pp. 905-914 . https://doi.org/10.1056/NEJMoa2033130 Lundgren, J D, Grund, B, Barkauskas, C E, Holland, T L, Gottlieb, R L, Sandkovsky, U, Brown, S M, Knowlton, K U, Self, W H, Files, D C, Jain, M K, Benfield, T, Bowdish, M E, Leshnower, B G, Baker, J V, Jensen, J-U, Gardner, E M, Ginde, A A, Harris, E S, Johansen, I S, Markowitz, N, Matthay, M A, Østergaard, L, Chang, C C, Davey, V J, Goodman, A, Higgs, E S, Murray, D D, Murray, T A, Paredes, R, Parmar, M K B, Phillips, A N, Reilly, C, Sharma, S, Dewar, R L, Teitelbaum, M, Wentworth, D, Cao, H, Klekotka, P, Babiker, A G, Gelijns, A C, Kan, V L, Polizzotto, M N, Thompson, B T, Lane, H C, Neaton, J D, TICO Study Group, Nielsen, H, ACTIV-3/TICO LY-CoV555 Study Group & Writing Commitee 2021, ' A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 ', The New England Journal of Medicine, vol. 384, no. 10, pp. 905-914 . https://doi.org/10.1056/NEJMoa2033130 Lundgren, J D, Grund, B, Barkauskas, C E, Holland, T L, Gottlieb, R L, Sandkovsky, U, Brown, S M, Knowlton, K U, Self, W H, Files, D C, Jain, M K, Benfield, T, Bowdish, M E, Leshnower, B G, Baker, J V, Jensen, J U, Gardner, E M, Ginde, A A, Harris, E S, Johansen, I S, Markowitz, N, Matthay, M A, Østergaard, L, Chang, C C, Davey, V J, Goodman, A, Higgs, E S, Murray, D D, Murray, T A, Paredes, R, Parmar, M K B, Phillips, A N, Reilly, C, Sharma, S, Dewar, R L, Teitelbaum, M, Wentworth, D, Cao, H, Klekotka, P, Babiker, A G, Gelijns, A C, Kan, V L, Polizzotto, M N, Thompson, B T, Lane, H C, Neaton, J D & ACTIV-3/TICO LY-CoV555 Study Group 2021, ' A neutralizing monoclonal antibody for hospitalized patients with Covid-19 ', New England Journal of Medicine, vol. 384, no. 10, pp. 905-914 . https://doi.org/10.1056/NEJMoa2033130